9 citations
,
March 2017 in “Journal of Visualized Experiments” The assay effectively identifies compounds that affect immune cell activation.
39 citations
,
January 2019 in “Journal of the American Academy of Dermatology” Tofacitinib may help treat severe childhood alopecia areata, but risks require careful consideration.
September 2013 in “Neurodegenerative disease management” Teriflunomide is effective and generally safe for treating relapsing multiple sclerosis, reducing relapse rates and disability progression.
130 citations
,
February 2018 in “Journal of Investigative Dermatology” Tofacitinib may help treat severe hair loss, but more research is needed.
Mealworm extract may help prevent hair loss and promote hair growth due to its antioxidant activity.
February 2005 in “Journal of the American Academy of Dermatology”
August 2024 in “Cell Death and Disease” Activating TLR9 helps heal wounds and regrow hair by using specific immune cells.
4 citations
,
February 2022 in “PeerJ” Hair follicle stem cell transplants can reverse liver cirrhosis by blocking harmful cell activation.
27 citations
,
May 2011 in “Journal of Investigative Dermatology” TCHHL1 is a protein important for hair growth, found in hair follicles.
June 2025 in “Dermatologic Surgery” GFC improves hair quickly, while PRP offers longer-lasting benefits; using both sequentially is recommended.
March 2014 in “Journal of The American Academy of Dermatology” Tavaborole is a safe and effective toenail fungus treatment, with the 5% solution being the best option.
4 citations
,
January 2023 in “Journal of Clinical Investigation” Specific mutations in a receptor cause facial abnormalities and hair loss.
October 2025 in “Plastic & Reconstructive Surgery” MNC-QQ cell therapy improved hair growth and quality of life in men with androgenic alopecia without adverse effects.
79 citations
,
September 2018 in “Dermatologic therapy” Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.
June 2023 in “Zenodo (CERN European Organization for Nuclear Research)” December 2014 in “Journal of Biomedical Research” Recombinant thymosin β4 promotes blood vessel growth and reduces muscle damage.
December 2015 in “PLOS ONE” 159 citations
,
July 2014 in “Molecular pharmaceutics” New micelle nanocarriers deliver Tacrolimus more effectively to skin layers for psoriasis treatment than the current Protopic ointment.
September 2023 in “Zenodo (CERN European Organization for Nuclear Research)”
June 2017 in “Journal of the American Academy of Dermatology” Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.
1 citations
,
July 2016 in “PubMed” Once-daily 5% minoxidil foam and twice-daily 2% minoxidil solution are similarly effective and safe for female pattern hair loss.
August 2019 in “Journal of the American Academy of Dermatology” Tofacitinib may help hair regrowth in alopecia areata, but more research is needed.
May 2025 in “Journal of Pharmacy And Bioallied Sciences” Tofacitinib effectively promotes hair regrowth in children with alopecia areata, but more research on long-term safety is needed.
November 2025 in “Journal of Investigative Dermatology” TEC kinases may help cause inflammation in vitiligo and could be targeted for treatment.
September 2018 in “Boletín médico del Hospital Infantil de México” Medical care for transgender youth should be individualized and supportive.
25 citations
,
August 2010 in “Journal of Biological Chemistry” Nuclear Factor I-C is important for controlling hair growth by affecting the TGF-β1 pathway.
12 citations
,
February 2023 in “Stem Cell Research & Therapy” HGF-modified hair follicle stem cells help brain recovery after injury in rats.
17 citations
,
January 2019 in “Dermatologic Therapy” Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.
October 2025 in “Frontiers in Artificial Intelligence” "HairSentinel" accurately detects hairfall trends using simple user data, helping identify health risks early.
June 2023 in “Zenodo (CERN European Organization for Nuclear Research)”